TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17827960
Drug: Supervised toothbrushing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised toothbrushing once a day at school with 1,000 ppm fluoride toothpaste and a home support package encouraging twice-daily toothbrushing
Study: 12452235
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg epidural morphine
Study: 10510952
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg b.d.)
Study: 6758825
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg twice daily for 2 weeks)
Study: 28328847
Drug: Topical 0.15%
Normalized name: menthol topical 0.15% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.15% isopropyl unoprostone (IU) used 3 times a day for 54 weeks
Study: 23317926
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein drink (20 g whey protein, 20 g carbohydrates)
Study: 23317926
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein drink (20 g milk protein, 20 g carbohydrates)
Study: 23317926
Drug: Carbohydrate drink
Normalized name: Ensure Pre-Surgery Clear Carbohydrate Drink (Strawberry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate drink (40 g carbohydrates)
Study: 21501517
Drug: IFNβ‐1a 22
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1a 22 mcg (low dose, LD)
Study: 21501517
Drug: IFNβ‐1a 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNβ‐1a 44 mcg (high dose, HD)
Study: 19524253
Drug: Mental verbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental verbs with strong nonfactive semantics (e.g., /ji5‐wai4/ 'falsely think')
Study: 17766523
Drug: Hudson prong
Normalized name: ADAPTER,MULTI HUDSON #1422
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hudson prong bubble continuous positive airway pressure therapy
Study: 17766523
Drug: Headbox oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headbox oxygen treatment (standard care)
Study: 12930116
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium phosphate (2 mg)
Study: 12930116
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (10.5 mg)
Study: 12930116
Drug: Hydrocortisone sodium
Normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone sodium succinate (50 mg)
Study: 9022603
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of recombinant FSH (Puregon)
Study: 9022603
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of recombinant FSH (Puregon)
Study: 30171823
Drug: Joint replacement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint replacement, past use of steroids, acid reflux/GERD
Study: 28635218
Drug: Budesonide nasal
Normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide nasal spray treatment
Study: 28635218
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of 3.0% saline nasal irrigation and budesonide nasal spray
Study: 26232815
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (topical sodium chloride, timolol, and betamethasone)
Study: 26232815
Drug: Systemic normobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic normobaric oxygen at a flow rate of 10 L/min for 1 hour twice daily for 3 weeks in addition to conventional therapy
Study: 26232815
Drug: Transcorneal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcorneal oxygen at a flow rate of 5 L/min for 1 hour twice daily for 3 weeks in addition to conventional therapy
Study: 23927913
Drug: Risedronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (2.5 or 5 mg daily for 1 year)
Study: 21926632
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily for 21 days (period 1)
Study: 21926632
Drug: Darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 800/100 mg once daily for 14 days (period 2)
Study: 21926632
Drug: Darunavir/ritonavir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darunavir/ritonavir 800 mg once daily (period 3)
Study: 21926632
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily (group 1)
Study: 8891011
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine at 3 mg/kg/day
Study: 8891011
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% beta‐methasone‐17,21‐dipropionate (BDP) cream
Study: 1898717
Drug: Pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 20 mg/d (increased to 40 mg/d for some patients)
Study: 1898717
Drug: Bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg/d
Study: 6601256
Drug: Sulfisoxazole, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfisoxazole, 75 mg/kg/d in two divided doses for 3 months
Study: 28895787
Drug: Internet-based Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based Acceptance and Commitment Therapy (8 weeks)
Study: 24947578
Drug: Cognitive pc-training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive pc-training in addition to conventional treatment
Study: 22752440
Drug: Mg-0 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-0 (100 mL of normal saline)
Study: 22752440
Drug: Mg-25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-25 (25 mg/kg magnesium sulfate)
Study: 22752440
Drug: Mg-50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-50 (50 mg/kg magnesium sulfate)
Study: 18451774
Drug: Antioxidant supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplement (1 g vitamin C/800 IU vitamin E)
Study: 12854881
Drug: Cetirizine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (30 mg a day, 3 times a day for 15 days)
Study: 8916975
Drug: Antigenemia-guided ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antigenemia-guided ganciclovir treatment (placebo group)
Study: 8916975
Drug: Ganciclovir administered
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir administered at engraftment (ganciclovir group)
Study: 8916975
Drug: Antigenemia-guided ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antigenemia-guided ganciclovir treatment
Study: 8916975
Drug: Ganciclovir administered
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganciclovir administered at engraftment
Study: 1726208
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 200mg twice daily for 7 to 14 days
Study: 1726208
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 400mg twice daily for 7 to 14 days
Study: 6356004
Drug: Bicillin C‐R,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicillin C‐R, 50,000 U/kg intramuscularly, followed by penicillin V, 100 mg/kg/d, orally four times a day for three days
Study: 30233001
Drug: Corrected‐Assisted‐Synchronized‐Periodic (CASP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corrected‐Assisted‐Synchronized‐Periodic (CASP) therapy
Study: 24942646
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 mcg oral Se tablets, twice daily)
Study: 22318373
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (9 sessions over 6 weeks including joint mobilization, exercises, and massage)
Study: 20051951
Drug: Prostate cancer
Normalized name: Leuprolide Acetate 22.5mg Lyophilisate for suspension for injection [Prostate Cancer] with Diluent, Transfer Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate cancer screening with PSA serum test (cutoff level of 4.0 ng/ml)
Study: 18034989
Drug: Losartan (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50‐100 mg)
Study: 9734619
Drug: Recombinant insulin‐like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant insulin‐like growth factor‐1 (rhIGF‐1)
Study: 9734619
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of recombinant growth hormone (rhGH) plus recombinant IGF‐1
Study: 30794553
Drug: NSAID gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID gel (diclofenac sodium 1%)
Study: 27503605
Drug: Remind-to-move (RTM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remind-to-move (RTM) treatment; 25 children, 75 hours over 3 weeks
Study: 27503605
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy (CIMT); 24 children, 75 hours over 3 weeks
Study: 23186556
Drug: Mindfulness- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness- and body-psychotherapy-based group treatment
Study: 9052580
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) replacement therapy (2 mg/day for 12 weeks)
Study: 27835719
Drug: Taurine 4
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine 4 g once daily for 12 weeks
Study: 17162333
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations including Solu Q10
Study: 12796021
Drug: CK‐19 mRNA-positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CK‐19 mRNA-positive cells detected in peripheral blood after adjuvant chemotherapy
Study: 10824554
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of anticancer agents
Study: 10824554
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of chemotherapy and thoracic irradiation
Study: 10824554
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of anticancer agents with thoracic irradiation
Study: 10824554
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents demonstrating antitumor activity against lung cancer
Study: 8504648
Drug: Papaverine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine (60 mg/500 mL)
Study: 3032033
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with chest radiation therapy (Cyclophosphamide, methotrexate, lomustine, vincristine, adriamycin, procarbazine; chest irradiation to 40 Gy in 15 fractions over 3 weeks)
Study: 3032033
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Cyclophosphamide, methotrexate, lomustine, vincristine, adriamycin, procarbazine)
Study: 26906747
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg primaquine
Study: 26906747
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg primaquine
Study: 26906747
Drug: 0.0625 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0625 mg/kg primaquine
Study: 26906747
Drug: 0.125 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/kg primaquine
Study: 26906747
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg/kg primaquine)
Study: 19190547
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.5 mg, 3 monthly injections)
Study: 19190547
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab plus PDT (0.5 mg, 3 monthly injections + 1 session of PDT)
Study: 19190547
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone plus PDT (4 mg, 1 injection + 1 session of PDT)
Study: 17277240
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise program (twice‐weekly treadmill assessments from 4 to 10 weeks postoperatively)
Study: 7750667
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg lansoprazole
Study: 8198269
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine (15 mg)
Study: 8198269
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine (22.5 mg)
Study: 29193553
Drug: AB-102 (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-102 (novel topical solution containing a high concentration of a weak α1 agonist)
Study: 29193553
Drug: Phenylephrine (previously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (previously used topical treatment)
Study: 26692322
Drug: High Intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intake (HI) group, consuming three cups (600 mL) of black tea per day
Study: 26692322
Drug: Low Intake
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intake (LI) group, administered 1 cup (200 mL) of black tea per day
Study: 18400558
Drug: CHOP-like chemotherapy
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-like chemotherapy alone
Study: 18400558
Drug: CHOP-like chemotherapy
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP-like chemotherapy with rituximab
Study: 16809805
Drug: Dolasetron 100
Normalized name: dolasetron 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 100 mg on day 1
Study: 16809805
Drug: Dolasetron 100
Normalized name: dolasetron 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 100 mg plus aprepitant 125 mg on day 1, aprepitant 80 mg on days 2-3
Study: 1497392
Drug: Heparin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin with warfarin
Study: 29651784
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) for CRF
Study: 26815179
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate (NaHCO3) 300 mg · kg(‐1) in 450 ml of flavored water
Study: 26815179
Drug: Placebo (NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 270 mg · kg(‐1) body mass)
Study: 20637534
Drug: Biomechanical device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomechanical device treatment
Study: 17576843
Drug: Bevirimat (BVM)
Normalized name: Bevirimat
DrugBank: Bevirimat (DB06581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevirimat (BVM) 25 mg
Study: 17576843
Drug: Bevirimat (BVM)
Normalized name: Bevirimat
DrugBank: Bevirimat (DB06581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevirimat (BVM) 50 mg
Study: 17576843
Drug: Bevirimat (BVM)
Normalized name: Bevirimat
DrugBank: Bevirimat (DB06581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevirimat (BVM) 100 mg
Study: 17576843
Drug: Bevirimat (BVM)
Normalized name: Bevirimat
DrugBank: Bevirimat (DB06581)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevirimat (BVM) 250 mg
Study: 12006727
Drug: Complementary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary treatment (herbal remedy Sinupret and homeopathic remedy Cinnabaris 3X)
Study: 12006727
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (antibiotics, secretolytics, symptomimetics)
Study: 7546837
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with autologous bone marrow stem cell support
Study: 7546837
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of polychemotherapy
Study: 2182959
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg p.o.)
Study: 2182959
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg p.o.) + Naloxone (2.8 mg i.v. in 5 h)
Study: 2182959
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral and i.v.)
Study: 6456068
Drug: Mezlocillin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin (1.5 gm) administered intramuscularly every six hours for seven days
Study: 6456068
Drug: Ticarcillin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin (2 gm) administered intramuscularly every six hours for seven days
Study: 28790162
Drug: Annual screening
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual screening examinations including laboratory assessments and various imaging modalities (e.g. CT, MRI, scintigraphy and EUS) for MEN1 patients.
Study: 22898358
Drug: SILCS single‐sided
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILCS single‐sided gel delivery
Study: 22898358
Drug: SILCS double‐sided
Approvals — FDA: no, EMA: no, PMDA: no
Description: SILCS double‐sided gel delivery
Study: 1293732
Drug: Ivermectin (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (multiple doses)
Study: 1293732
Drug: Ivermectin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (single dose)
Study: 27015909
Drug: Sustained-release dexamfetamine
Normalized name: dexamfetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release dexamfetamine (60 mg/day)
Study: 27015909
Drug: Sustained-release dexamfetamine
Normalized name: dexamfetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release dexamfetamine
Study: 12059886
Drug: Epidural sufentanil-ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil-ropivacaine infusion with epinephrine (n=32)
Study: 12059886
Drug: Epidural sufentanil-ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil-ropivacaine infusion without epinephrine (n=29)
Study: 8126039
Drug: Hypotensive epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive epidural anesthesia, external pneumatic-compression boots, and aspirin (Group I)
Study: 8126039
Drug: Hypotensive epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotensive epidural anesthesia and aspirin (Group II)
Study: 2531270
Drug: SPG administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPG administered intramuscularly 40mg/week
Study: 779750
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (Calciparine)
Study: 22739993
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided steroid injection
Study: 22739993
Drug: Palpation guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation guided steroid injection
Study: 22739993
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active treatment groups (ultrasound guided and unguided)
Study: 16332655
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary calcium intake (1000-1400 mg/d)
Study: 16332655
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary calcium intake (<800 mg/d, control)
Study: 9873847
Drug: low-dose concentrate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose concentrate at 25 IU kg‐1 twice weekly
Study: 2664088
Drug: Intravenous methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylphenidate (MTP)
Study: 850062
Drug: Preparation (experimental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation (experimental group)
Study: 23403717
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone withdrawal (THW)
Study: 17042908
Drug: Tulobuterol patch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol patch, 2 mg once daily
Study: 17042908
Drug: Salmeterol, 50
Normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 50 mg twice daily
Study: 23682096
Drug: LB03002 (SR-hGH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 (SR-hGH) administered once weekly at a dose of 0.5 mg/kg
Study: 23682096
Drug: Daily rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhGH administered for 6 consecutive days at a total of 0.21 mg/kg per week
Study: 21235334
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg (and another 200 mg 12 hours after the first dose)
Study: 17875873
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolevulinate PDT